Suppr超能文献

miR-127-3p和miR-376a-3p在骨肉瘤细胞中的肿瘤抑制功能

Tumor Suppressor Function of miR-127-3p and miR-376a-3p in Osteosarcoma Cells.

作者信息

Fellenberg Joerg, Lehner Burkhard, Saehr Heiner, Schenker Astrid, Kunz Pierre

机构信息

Center for Orthopedics, Trauma Surgery and Paraplegiology, University of Heidelberg, 69118 Heidelberg, Germany.

Clinic for Shoulder and Elbow Surgery, Catholic Hospital Mainz, Rhineland-Pfalz, 55131 Mainz, Germany.

出版信息

Cancers (Basel). 2019 Dec 14;11(12):2019. doi: 10.3390/cancers11122019.

Abstract

Since the introduction of high-dose chemotherapy about 35 years ago, survival rates of osteosarcoma patients have not been significantly improved. New therapeutic strategies replacing or complementing conventional chemotherapy are therefore urgently required. MicroRNAs represent promising targets for such new therapies, as they are involved in the pathology of multiple types of cancer, and aberrant expression of several miRNAs has already been shown in osteosarcoma. In this study, we identified silencing of miR-127-3p and miR-376a-3p in osteosarcoma cell lines and tissues and investigated their role as potential tumor suppressors in vitro and in vivo. Transfection of osteosarcoma cells ( = 6) with miR-127-3p and miR-376a-3p mimics significantly inhibited proliferation and reduced the colony formation capacity of these cells. In contrast, we could not detect any influence of miRNA restoration on cell cycle and apoptosis induction. The effects of candidate miRNA restoration on tumor engraftment and growth in vivo were analyzed using a chicken chorioallantoic membrane (CAM) assay. Cells transfected with mir-127-3p and miR-376a-3p showed reduced tumor take rates and tumor volumes and a significant decrease of the cumulative tumor volumes to 41% and 54% compared to wildtype cells. The observed tumor suppressor function of both analyzed miRNAs indicates these miRNAs as potentially valuable targets for the development of new therapeutic strategies for the treatment of osteosarcoma.

摘要

大约35年前高剂量化疗引入以来,骨肉瘤患者的生存率并未得到显著提高。因此,迫切需要替代或补充传统化疗的新治疗策略。微小RNA是这类新疗法的有前景的靶点,因为它们参与多种癌症的病理过程,并且在骨肉瘤中已经显示出几种微小RNA的异常表达。在本研究中,我们在骨肉瘤细胞系和组织中鉴定出miR-127-3p和miR-376a-3p的沉默,并在体外和体内研究了它们作为潜在肿瘤抑制因子的作用。用miR-127-3p和miR-376a-3p模拟物转染骨肉瘤细胞(=6)显著抑制了这些细胞的增殖并降低了其集落形成能力。相比之下,我们未检测到微小RNA恢复对细胞周期和凋亡诱导的任何影响。使用鸡胚绒毛尿囊膜(CAM)试验分析了候选微小RNA恢复对体内肿瘤植入和生长的影响。与野生型细胞相比,用mir-127-3p和miR-376a-3p转染的细胞显示出降低的肿瘤接种率和肿瘤体积,并且累积肿瘤体积显著降低至41%和54%。所观察到的两种分析的微小RNA的肿瘤抑制功能表明这些微小RNA作为开发骨肉瘤治疗新策略的潜在有价值靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d7/6966509/8907337af44a/cancers-11-02019-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验